Brain/Nervous System Cancer Clinical Trials


Study Title: A071701 Genetic Testing in Guiding Treatment for Patients With Brain Metastases
Primary/Site/Co-Investigator: Alissa Thomas, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Study Title: UVMCC 1904 Tissue Bank for Benign and Malignant Tumors of the Nervous System
Primary/Site/Co-Investigator: Alissa Thomas, MD
For more Information About this Trial: call the UVM Cancer Center Clinical Trials Office at (802)656-4414 ext. 2
To Learn More or Enroll: Call (802)656-4414 ext. 2

Study Title: ML29496 Maintenance Obinutuzumab for Primary Central Nervous System Lymphoma Complete Responders (OHSU/Genentech) SUSPENDED
Primary/Site/Co-Investigator: Alissa Thomas, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Study Title: Trident EF-32 - Randomized, Phase III, Open-label Study of Tumor Treating Fields (Optune, 200kHz) Concomitant with Radiation Therapy and Temozolomide for the Treatment of Newly Diagnosed Glioblastoma (COMING SOON)
Primary/Site/Co-Investigator: Alissa Thomas, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Study Title: NRG BN007 A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide in Patients With Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma (COMING SOON)
Primary/Site/Co-Investigator: Alissa Thomas, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Breast Cancer Clinical Trials


Study Title: A071701 Genetic Testing in Guiding Treatment for Patients With Brain Metastases
Primary/Site/Co-Investigator: Alissa Thomas, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Study Title: A011202: A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Primary/Site/Co Investigator: Michelle Sowden, DO
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Study Title: AFT25 COMET: Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial for Low Risk DCIS: A Phase III Prospective Randomized Trial
Primary/Site/Co-Investigator: Jessica Cintolo-Gonzalez, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Study Title: JZLA EMBER - A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination with Abemaciclib to Patients with ER+, HER2- Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers
Primary/Site/Co-Investigator: Peter Kaufman, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Study Title: A221505 Phase III Randomized Trial of Hypofractionated Post Mastectomy Radiation with Breast Reconstruction
Primary/Site/Co-Investigator: Carl Nelson, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Study Title: NRG BR003 A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
Primary/Site/Co-Investigator: Marie Wood, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Study Title: ACT 16106 Phase 2 Window Study of Two Dose Levels of SAR439859 (SERD) versus Letrozole in Newly Diagnosed Pre-operative Post-menopausal Patients with ER Positive, HER2 Negative Primary Breast Cancer (COMING SOON)
Primary/Site/Co-Investigator: Peter Kaufman, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Bladder Cancer Clinical Trials


Study Title: D933RC00001- NIAGARA-A Phase III Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine & Cisplatin for Neoadjuvant Treatment Followed by Durvalumab Alone for Adjuvant Treatment in Patients with Muscle-Invasive Bladder Cancer (NIAGARA)
Primary/Site/Co-Investigator: Steven Ades, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Study Title: MK3475-676: A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475 in Combination with Bacillus Calmette-Guerin (BCG) in Participants with High-risk Non-muscle Invasive Bladder Cander (HR NMIBC) that is Persistent or Recurrent Following BCG Induction (KEYNOTE-676)
Primary/Site/Co-Investigator: Scott Perrapato, DO
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Study Title: A031501 Phase III Randomized Adjuvant Study of MK-3475 (Pembrolizumab) in Muscle Invasive and Locally Advanced Urothelial Carcinoma (AMBASSADOR) Versus Observation
Primary/Site/Co-Investigator: Steven Ades, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Endometrial Cancer Clinical Trials


Study Title: NRG GY018 A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III OR IVA, Stage IVB or Recurrent Endometrial Cancer
Primary/Site/Co-Investigator: Cheung Wong, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Gastrointestinal Cancer Clinical Trials


Study Title: EA2165: A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
Primary/Site/Co-Investigator: Maura Barry, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Study Title: UVMCC 1901, Use of digital PET scanning to identify lymphatic metastases in colon cancer
Primary/Site/Co Investigator: Peter Cataldo, MD
For more Information: call the UVM Cancer Center Clinical Trials Office at (802)656-4414 ext. 2
To Learn More or Enroll: Call (802)656-4414 ext. 2

Head and Neck Cancer Clinical Trials


Study Title: MK-3475-689-A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC)
Primary/Site/Co-Investigator: Mirabelle Sajisevi, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Kidney Cancer Clinical Trials


Study Title: A031704: PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab vs. VEGF TKI Cabozantinib with Nivolumab:  A Phase III Trial in Metastatic Untreated Renal Cell Cancer (PDIGREE)
Primary/Site/Co-Investigator: Shahid Ahmed, MBBS
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Study Title: EA8143: A Phase 3 Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
Primary/Site/Co-Investigator: Scott Perrapato, DO, FACOS
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Leukemia Cancer Clinical Trials


Study Title: D18-11141: Phase III Randomized Trial of DFP-10917 vs. Non-Intensive Reinduction (LoDAC, Azacitidine, Decitabine) or Intensive Reinduction (High and Intermediate Dose Cytarabine Regimens) for Acute Myelogenous Leukemia Patients in Second or Third Salvage
Primary/Site/Co-Investigator: Sakshi Jasra, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Study Title: PrE0905 Randomized Trial of Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia (AML) (COMING SOON)
Primary/Site/Co-Investigator: Elvira Umyarova, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Lung Cancer Clinical Trials


Study Title: D9103C00001: A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with Stage I/II Non-small Cell Lung Cancer (PACIFIC4/RTOG-3515)
Primary/Site/Co-Investigator: Nat Lester-Coll, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Study Title: A071701 Genetic Testing in Guiding Treatment for Patients With Brain Metastases
Primary/Site/Co-Investigator: Alissa Thomas, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Study Title: NRG-LU005 Chemoradiation With or Without Atezolizumab in Treating Patients With Limited Stage Small Cell Lung Cancer
Primary/Site/Co-Investigator: Chris Anker, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Study Title: LUNGMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (LUNG-MAP Screening Study)
Primary/Site/Co-Investigator: Hibba Rehman, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Study Title: EA5163 - A Randomized, Phase III Study of Firstline Immunotherapy alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer with Immunobiomarker SIGNature-driven Analysis
Primary/Site/Co Investigator: Farrah Khan, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Study Title: A151216 Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (15-157 ALCHEMIST)
Primary/Site/Co Investigator: Hibba Rehman, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Study Title: ECOG 4512 Testing the Addition of the Drug Crizotinib After Surgery to Remove ALK-Positive Non-Small Cell Lung Cancer (ALCHEMIST)
Primary/Site/Co Investigator: Hibba Rehman, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Lymphoma Clinical Trials


Study Title: A051701: Randomiized Phase II/III Study of Venetoclax (ABT 199) Plus Chemoinnumotherapy for MYC/BCL2 Double-Hit and Double-Expressing Lymphomas (Currently Suspended)
Primary/Site/Co-Investigator: Julian Sprague, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Study Title: EA4151: A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission
Primary/Site/Co Investigator: Julian Sprague, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Study Title: EA4181 A Randomized 3-Arm Phase II Study Comparing 1)Bendamustine, Rituximab, and High Dose Cytarabine (BR/CR) 2) Bendamustine, Rituximab, High Dose Cytarabine, and Acalabrutinib (BR/CR-A) 3) Bendamustine, Rituximab, and Acalabrutinib (Br-A) in Patients Less Than or Equal to 70 Years Old with Untreated Mantle Cell Lymphoma (COMING SOON)
Primary/Site/Co Investigator: Julian Sprague, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Melanoma Clinical Trials


Study Title: S1801 - A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
Primary/Site/Co-Investigator: Shahid Ahmed, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Study Title: A071701 Genetic Testing in Guiding Treatment for Patients With Brain Metastases
Primary/Site/Co-Investigator: Alissa Thomas, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Study Title: UVMCC 1912 - Using Circulating Tumor DNA (ctDNA) to Predict Minimal Residual Disease, Recurrent Disease, and Clinical Outcomes in Patients with High Risk Malignant Melanoma
Primary/Site/Co-Investigator: Jessica Cintolo-Gonzalez, MD
To Learn More or Enroll: Call (802)656-4414 ext. 2

Ovarian Cancer Clinical Trials


Study Title: GOG 3018 The OVAL Study: A Randomized Controlled, Double Arm, Double Blind Multi-center Study of Ofranergene Obadenovec (VB-111) Combined with Paclitaxel vs Paclitaxel Combined with Placebo for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer
Primary/Site/Co-Investigator: Cheung Wong, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Prostate Cancer Clinical Trials


Study Title: NRG GU005: Phase III Image-Guided RadiationTherapy (IGRT) and Stereotactic Body Radiation Therapy (SBRT) vs. IGRT and Hypofractionated Intensity-Modulated Radiation Therapy (IMRT) for localized intermediate risk prostate cancer
Primary/Site/Co-Investigator: Nataniel Lester-Coll, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Study Title: S1802: Phase III Randomized Trial of Standard Systemic Therapy (SST) versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) or the Primary Tumor in Metastatic Prostate Cancer
Primary/Site/Co-Investigator: Nataniel Lester-Coll, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Rectal/Anal Cancer Clinical Trials


Study Title: Wash U. Non-Operative Management and Early Response Assessment in Rectal Cancer (NOM-ERA) (COMING SOON)
Primary/Site/Co-Investigator: Christopher Anker, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Study Title: EA 2182 A Randomized Phase II Study of De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE) (COMING SOON)
Primary/Site/Co-Investigator: Krista Evans, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

About Us

Services

FAQs

Contact Us

 

Trials by Cancer Type

Click below to view open cancer trials by type. 

Brain/Nervous System Breast Bladder Endometrial Gastrointestinal Head and Neck Kidney Leukemia Lung Lymphoma Melanoma Ovarian Pediatric Prostate Rectal/Anal

Enroll Now

If you have any questions or would like to enroll in one of these clinical trials, please call (802) 656-4414 ext. 2.